Home / Companies / News / Biocon's insulin biosimilar Glargine gets preference in top US formulary

Biocon's insulin biosimilar Glargine gets preference in top US formulary

The USFDA had approved biosimilar Insulin Glargine-yfgn injection (Semglee) as the first interchangeable biosimilar product in July this year

Premium

2 min read Last Updated : Oct 21 2021 | 12:19 PM IST

An insulin biosimilar called Glargine, co-developed by Biocon Biologics and US pharma company Viatris, will be listed by pharmacy benefit management organisation Express Scripts as a preferred insulin brand on its National Preferred Formulary for diabetic patients in the US.

Drug formularies are a set of generic and brand name medicines which are preferred by a health plan. They help patients in choosing a less expensive drug when a cheaper alternative could be used to treat a condition just as well.

“The inclusion of our interchangeable biosimilar insulin glargine in Express Scripts’ National Preferred Formulary (NPF) in the US is

Topics : Biocon USFDA

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in